Yazar "Ozturk, Banu Turgut" seçeneğine göre listele
Listeleniyor 1 - 20 / 24
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Apremilast for Behcet's Syndrome - A Phase 2, Placebo-Controlled Study(MASSACHUSETTS MEDICAL SOC, 2015) Hatemi, Gulen; Melikoglu, Melike; Tunc, Recep; Korkmaz, Cengiz; Ozturk, Banu Turgut; Mat, Cem; Merkel, Peter A.BACKGROUND Oral ulcers, the hallmark of Behcet's syndrome, can be resistant to conventional treatment; therefore, alternative agents are needed. Apremilast is an oral phosphodiesterase-4 inhibitor that modulates several inflammatory pathways. METHODS We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Behcet's syndrome who had two or more oral ulcers were randomly assigned to receive 30 mg of apremilast twice daily or placebo for 12 weeks. This regimen was followed by a 12-week extension phase in which the placebo group was switched to apremilast and a 28-day post-treatment observational follow-up phase. The patients and clinicians were unaware of the study assignments throughout the trial. The primary end point was the number of oral ulcers at week 12. Secondary outcomes included pain from these ulcers (measured on a 100-mm visual-analogue scale, with higher scores indicating worse pain), the number of genital ulcers, overall disease activity, and quality of life. RESULTS The mean (+/- SD) number of oral ulcers per patient at week 12 was significantly lower in the apremilast group than in the placebo group (0.5 +/- 1.0 vs. 2.1 +/- 2.6) (P<0.001). The mean decline in pain from oral ulcers from baseline to week 12 was greater with apremilast than with placebo (-44.7 +/- 24.3 mm vs. -16.0 +/- 32.5 mm) (P<0.001). Nausea, vomiting, and diarrhea were more common in the apremilast group (with 22, 9, and 12 incidents, respectively, among 55 patients) than in the placebo group (with 10, 1, and 2 incidents, respectively, among 56 patients), findings that were similar to those in previous studies of apremilast. There were two serious adverse events in patients receiving apremilast. CONCLUSIONS Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Behcet's syndrome. This preliminary study was neither large enough nor long enough to assess long-term efficacy, the effect on other manifestations of Behcet's syndrome, or the risk of uncommon serious adverse events.Öğe Apremilast For The Treatment Of Behcet's Syndrome: A Phase II Randomized, Placebo-Controlled, Double-Blind Study(WILEY-BLACKWELL, 2013) Hatemi, Gulen; Melikoglu, Melike; Tunc, Recep; Korkmaz, Cengiz; Ozturk, Banu Turgut; Mat, Cem; Merkel, Peter A.[Abstract not Available]Öğe Assessment of capsular block syndrome with Scheimpflug camera(CANADIAN OPHTHAL SOC, 2009) Kamis, Umit; Ozturk, Banu Turgut; Sahin, Alparslan; Kerimoglu, Hurkan; Okudan, Suleyman[Abstract not Available]Öğe Association of an Endothelial Nitric Oxide Synthase Gene Polymorphism with Diabetic Retinopathy(KAMLA-RAJ ENTERPRISES, 2018) Inan, Sibel; Zengin, Nazmi; Ozturk, Banu Turgut; Kerimoglu, Hurkan; Unlu, Ali; Dogan, IsmetThe association of the endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with the severity of diabetic retinopathy (DRP) and macular edema (DME) was investigated. One hundred-seven patients with type-2 diabetes mellitus were included. Forty-five patients served as a control group. eNOS G894T gene polymorphism was analysed by polymerase chain reaction. The mean age was 55.8 +/- 9.4 years in the study group and 51.8 +/- 9.7 years in the control group. There was no significant difference in the genotypes between the diabetic and the control group, or between the non-DRP group and the DRP group. The frequency of the G allele was higher in the proliferative DRP group than that in the non-proliferative DRP group. The GG genotype of G894T gene polymorphism was associated with macular edema and hyperglycaemia. The eNOS G894T gene polymorphism seems to be associated with the DME and unregulated hyperglycaemia.Öğe Association of Apolioprotein E Polymorphism with Intravitreal Ranibizumab Treatment Outcomes in Age-Related Macular Degeneration(KARGER, 2014) Bakbak, Berker; Ozturk, Banu Turgut; Zamani, Ayse Gul; Gonul, Saban; Gedik, Sansal; Yildirim, Selman; Okudan, Suleyman[Abstract not Available]Öğe Association of Apolipoprotein E Polymorphism with Intravitreal Ranibizumab Treatment Outcomes in Age-Related Macular Degeneration(TAYLOR & FRANCIS INC, 2016) Bakbak, Berker; Ozturk, Banu Turgut; Zamani, Ayse Gul; Gonul, Saban; Iyit, Neslihan; Gedik, Sansal; Yildirim, M. SelmanPurpose: Genetic factors are known to influence the response to anti-vascular endothelial growth factor (VEGF) treatment in exudative age-related macular degeneration (AMD). The current study was conducted to investigate the association of Apolipoprotein E (ApoE) polymorphism with the treatment response to ranibizumab for exudative AMD.Methods: One hundred nine eyes (109 patients, 59.6% male, mean age 63.847.22 years) treated with intravitreal ranibizumab injections were included in the analysis. Smoking status and lesion type were recorded. Patients were categorized into three groups according to visual acuity (VA) change at 6 months after the first injection: VA loss >5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Group 1); VA change between five ETDRS letters gain and loss (Group 2); VA improvement >5 ETDRS letters (Group 3). The association of ApoE gene polymorphisms with the three groups was evaluated.Results: Both smoking status and lesion type showed no significant association with VA change (p=0.12 and p=0.64, respectively). A lower frequency of 2 and a higher frequency of 4 were observed in Group 3 (2.9 and 25.7%, respectively). VA improvement with more than five ETDRS letters was significantly associated with the presence of the 4 genotype (p=0.01).Conclusions: This study demonstrated that carriers of the ApoE 4 polymorphism genotype show demonstrable improvement in VA after treatment with ranibizumab in exudative AMD. ApoE polymorphism identification may be used as a genetic screening to tailor individualized therapeutic approach for optimal treatment in neovascular AMD.Öğe Bilateral Papillophlebitis in a Patient with Mutation of Metilenetetrahydrofolate Reductase Enzyme(TURKISH OPHTHALMOLOGICAL SOC, 2016) Guzel, Huseyin; Ozturk, Banu Turgut; Gedik, Sansal; Bakbak, Berker; Beyoglu, Abdullah; Kocak, NadirPapillophlebitis is known as central retinal vein occlusion seen in young patients. It usually presents as unilateral optic disc edema with cotton wool spots and hemorrhage in the peripapillary region. As it may be due to many autoimmune and inflammatory causes, a thorough systemic evaluation of the patient is warranted. In this case report we describe a bilateral, simultaneous papillophlebitis case thought to be related to hyperhomocysteinemia secondary to C677T polymorphism of methylenetetrahyrofolate reductase enzyme.Öğe Comparison of Intravitreal Bevacizumab and Ranibizumab Treatment for Diabetic Macular Edema(MARY ANN LIEBERT, INC, 2011) Ozturk, Banu Turgut; Kerimoglu, Hurkan; Bozkurt, Banu; Okudan, SuleymanAim: The aim of this study was to compare the effects of bevacizumab and ranibizumab on visual function and macular thickness in patients with diabetic macular edema (DME). Methods: The data of diabetic patients who had been treated with bevacizumab for DME were reviewed. Those patients who received 1 injection of intravitreal bevacizumab and ranibizumab with at least 6-month interval were considered for enrollment. The best-corrected visual acuity (BCVA) assesment with Early Treatment Diabetic Retinopathy Study (ETDRS) chart and central subfield macular thickness (CSMT) measurement using optical coherence tomography-3 before and after the injections were recorded as outcome measures. Results: The study included 29 eyes of 29 patients with a mean age of 56.18 +/- 3.07 years. The median BCVA was 59 ETDRS letters and the median CSMT was 411 mu m preceeding the bevacizumab injection. At the 4th-6th week control after the injection, median BCVA increased to 61.50 ETDRS letters and the median CSMT decreased to 373 mu m. This change in BCVA and CSMT was found to be statistically significant (P = 0.029 and P = 0.011, respectively). The mean interval between bevacizumab and ranibizumab treatment was 9.54 +/- 2.64 months. Ranibizumab treatment increased the median BCVA from 53 to 66 ETDRS letters and decreased the median CSMT from 428 mu m to a level of 279 mu m, which were statistically significant (P < 0.001 and P < 0.001, respectively). The median change in BCVA was 4.5 ETDRS letters in the bevacizumab group and 6 ETDRS letters in the ranibizumab group (P = 0.58), whereas the median changes in CSMT were 41 and 100 mu m after bevacizumab and ranibizumab injections, respectively (P = 0.005). Conclusions: Bevacizumab and ranibizumab are both effective antivascular endothelial growth factor drugs preferred in the treatment of DME. Our comparison of both therapies on the same patients suggested that the effect on BCVA was not statistically different, but ranibizumab provided more decrease in CSMT.Öğe Comparison of the Effect of Unilateral Intravitreal Bevacizumab and Ranibizumab Injection on Diabetic Macular Edema of the Fellow Eye(MARY ANN LIEBERT, INC, 2013) Bakbak, Berker; Ozturk, Banu Turgut; Gonul, Saban; Yilmaz, Mevlut; Gedik, SansalPurpose: To find out whether intravitreally administered bevacizumab and ranibizumab affect the contralateral, untreated, eyes of patients with bilateral diabetic macular edema (DME). Methods: A retrospective review of patients with bilateral DME, who were treated with intravitreal bevacizumab or ranibizumab, was performed. All enrolled patients received intravitreal 1.25mg bevacizumab or 0.5mg ranibizumab in the eye with more severe macular edema. As outcome measures, best-corrected visual acuity (BCVA) was assessed with the Early Treatment Diabetic Retinopathy Study chart and central foveal thickness (CFT) measurement was obtained using optical coherence tomography-3 before and at 2 and 4 weeks after injections. Results: The study included 55 eyes of 55 patients who received bevacizumab (group 1) and 32 eyes of 32 patients who received ranibizumab (group 2). The mean age of the 55 patients [35 female (63.6%), 20 male (36.4%)] in group 1 was 54.3112.67 years, and the mean age of the 32 patients [20 female (62.5%), 12 male (37.5%)] in group 2 was 56.01 +/- 13.29 years. The median BCVA in the uninjected eye showed no statistically significant change at any visit after either bevacizumab or ranibizumab injection (P=0.302, P=0.582, respectively). In group 1, the median CFT in the uninjected eye was 417m at baseline; this was reduced to 401m at 2 weeks and 372m at 4 weeks. The change in CFT was found to be statistically significant (P=0.009). No statistically significant change was found in the median CFT of uninjected eyes of patients treated with ranibizumab (399, 403, and 407m before and at 2 and 4 weeks after treatment, respectively). Conclusions: Compared with ranibizumab, intravitreal administration of bevacizumab resulted in a greater decrease in macular thickness in the untreated eye, in patients with bilateral DME.Öğe Corneal specular microscopy findings in Behcet's disease(ASSOC RESEARCH VISION OPHTHALMOLOGY INC, 2014) Ozturk, Banu Turgut; Bozkurt, Banu; Beyoglu, Abdullah; Gonul, Saban; Okudan, Suleyman[Abstract not Available]Öğe Diurnal Variation of Anterior Chamber Flare(TURKISH OPHTHALMOLOGICAL SOC, 2015) Adam, Mehmet; Okka, Mehmet; Ozturk, Banu Turgut; Bozkurt, Banu; Kerimoglu, Hurkan; Pekel, Hamiyet; Okudan, SuleymanObjectives: To investigate the ideal time and reproducibility of anterior chamber flare measurements. Materials and Met-hods: Anterior chamber flare measurements were performed with laser flaremetre device at 8 am to 45 volunteers and these measurements were repeated on the same day at 12 pm and 4 pm. Results: Twenty- five (55.5%) of the volunteers were women and 20 (44.5%) were men; mean age was 28.67 +/- 7.40 (18- 49) years. The mean anterior chamber flare measurements taken following the ophthalmologic examination were 5.94 +/- 1.41 foton/msn at 8 am, 5.65 +/- 1.45 foton/msn at 12 pm, and 5.79 +/- 1.20 foton/msn at 4 pm. No statistical difference was found between the measurements (p=0.08). Subgroup analysis according to eye color, revealed no significant difference between flare measurements in brown, hazel, and green eyes (p=0.21). Correlation analysis demonstrated association between age and all flare measurements within the day (r=0.24, p=0.03; r=0.41, p=0.01, r=0.27, p=0.01). Conclusion: No significant diurnal change was detected in the flare measurements of our study subjects but positive correlation with age was observed. Hence, all flare measurements within a day are reliable and have high repeatability in healthy subjects.Öğe Effect of Apremilast on Quality of Life and Physical Function in Patients with Behcet's Syndrome.(WILEY-BLACKWELL, 2014) Hatemi, Gulen; Melikoglu, Melike; Tunc, Recep; Korkmaz, Cengiz; Ozturk, Banu Turgut; Mat, Cem; Merkel, Peter A.[Abstract not Available]Öğe The Effect of Hypothyroidism on Color Contrast Sensitivity: A Prospective Study(KARGER, 2015) Cakir, Mehtap; Ozturk, Banu Turgut; Turan, Elif; Gonulalan, Gulsum; Polat, Ilker; Gunduz, KemalBackground: Thyroid hormone has been shown to control retinal cone opsin expression, the protein of color vision, in adult rodents. Objectives: The aim of this study was to evaluate the effect of hypothyroidism on color contrast sensitivity in adult overt hypothyroid patients. Methods: Thirtyeight overt hypothyroid (31 females, 7 males) subjects and 20 euthyroid (16 females, 4 males) controls were studied prospectively. Color vision examination was performed by Chromatest, a software program analyzing the tritan (blueyellow) color contrast threshold (tritan CCT) and protan (redgreen) color contrast threshold (protan CCT). Color contrast sensitivity analyses of hypothyroid subjects were performed on admission and after L -thyroxine treatment when biochemical euthyroidism was achieved. Results: After a median period of 90 (90-210) days, 24 (19 females, 5 males) patients were euthyroid and eligible for a second color vision examination. Baseline tritan CCT and protan CCT values were significantly higher in the hypothyroid group compared to euthyroid controls, which clinically translates into impaired color contrast sensitivity (p < 0.001 and p < 0.001, respectively). There was a significant decrease in tritan CCT (p = 0.002) and protan CCT (p < 0.001) values in the hypothyroid group after euthyroidism was achieved, which denotes improvement in color contrast sensitivity. Conclusions: It is a novel finding of the current study that color contrast sensitivity is impaired in hypothyroidism and significantly improves after euthyroidism is achieved. (C) 2015 European Thyroid Association Published by S. Karger AG, BaselÖğe Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness(MOLECULAR VISION, 2009) Ozturk, Banu Turgut; Bozkurt, Banu; Kerimoglu, Hurkan; Okka, Mehmet; Kamis, Umit; Gunduz, KemalPurpose: To investigate the role of serum inflammatory cytokines and vascular endothelial growth factor (VEGF) in diabetic retinopathy (DR) and evaluate their relationship with macular thickness measurements obtained with optical coherence tomography (OCT). Methods: The study enrolled 28 healthy subjects (Group 1), 31 patients without DR (Group 2), 49 patients with nonproliferative DR (Group 3), and 46 patients with proliferative DR (Group 4). Macular profile was assessed with Stratus OCT-3 and the serum concentrations of VEGF and interleukin-1 alpha (IL-1 alpha), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), macrophage inflammatory protein (MIP-1 alpha), monocyte chemoattractant protein (MCP-1), and epidermal growth factor (EGF) were measured using multiplex bead immunoassay. Results: The median value of the visual acuity was 20/20 (Groups 1 and 2), and 20/100 (Group 3), and 20/125 (Group 4). The median value of central subfield macular thickness was estimated as 165.50 mu m in Group 1, 202.5 mu m in Group 2, 318 mu m in Group 3, and 310 mu m in Group 4. The median serum VEGF level, which was 98.20 pg/ml in Group 1, demonstrated a progressive rise to 125.37 pg/ml in Group 2, to 153.07 pg/ml in Group 3, and to 149.12 pg/ml in Group 4. Statistical significance was found between all groups (p<0.05) except between Groups 3 and 4 (p=0.87). The median levels of IL-1 alpha and IL-6 were zero in all groups. The median serum levels of IL-8, IL-10, MIP-1 alpha, and EGF revealed a wide range within each group but no statistical significance between the groups (p>0.05). The median serum levels of IL-8, IL-10, MIP-1 alpha, and EGF revealed a wide range within each group, however, no statistically significant relationship was found between the groups (p>0.05). The median values of the serum MCP-1 concentrations presented a statistically significant rise with the progression of DR (p=0.02). No correlation was found between macular thickness and serum cytokine and VEGF levels (p>0.05). Conclusions: Increased serum levels of VEGF and MCP-1 may act as a key regulator of DR and provide a potential tool for risk assessment in diabetic patients. Further studies that evaluate both vitreous and serum levels in various stages of DR are needed to provide a better understanding of the interaction between systemic and local inflammatory and angiogenic factors.Öğe Endogenous Brucella endophthalmitis: A case report(ELSEVIER SCIENCE BV, 2017) Oray, Merih; Cebeci, Zafer; Kir, Nur; Ozturk, Banu Turgut; Oksuz, Lutfiye; Tugal-Tutkun, IlknurBrucellosis may be associated with a wide range of ophthalmic manifestations including endophthalmitis, which is a sightthreatening condition that needs to be rapidly recognized and treated to avoid permanent visual loss. A 26-year-old female with a 6-month history of vision loss in the left eye was treated with high dose systemic corticosteroids and azathioprine with an initial misdiagnosis elsewhere. A dense vitreous haze with opacities at the posterior hyaloid and a wide area of retinochoroiditis led to the diagnosis of endogenous endophthalmitis at presentation to us. The vitreous sample and blood cultures demonstrated growth of Brucella melitensis. She received 6 months of systemic antibiotherapy, which resulted in resolution of inflammation; however, visual acuity remained poor due to irreversible damage. Infectious etiology, including brucellosis in endemic countries, has to be considered in the differential diagnosis before administering immunomodulatory therapy in patients with panuveitis of unknown origin.Öğe Evaluation of Retinal Nerve Fiber Layer Thickness with Optical Coherence Tomography in Type 1 Diabetes Mellitus Patients(ORTADOGU AD PRES & PUBL CO, 2011) Gonul, Saban; Ozkagnici, Ahmet; Ozturk, Banu Turgut; Kerimoglu, Hurkan; Sahin, AlparslanObjective: To evaluate retinal nerve fiber layer (RNFL) thickness changes of type 1 diabetes mellitus (DM) patients with and without diabetic retinopathy (DR). Material and Methods: One hundred-eighteen patients with type 1 DM and 49 age-matched control subjects were enrolled in the study. Ninety eight of 118 diabetic patients with DR were assigned as group 1 and the remaining 20 patients without DR were labeled as group 20 (n = 98). The RNFL thickness of all subjects were measured using optical coherence tomography (OCT). Results: The study included 118 type 1 DM patients with a mean age of 18.77 +/- 8.80 years. The mean age of 49 subjects in the control group was 18.71 +/- 5.72 (range 7-40) years. The mean RNFL thickness was 103.79 +/- 6.45 mu m in the control group, 100.00 +/- 11.93 mu m in group 1 and 85.59 +/- 19.81 mu m in group 2. The decrease in group 2 was found statistically significant (p < 0.001). The mean RNFL thickness in the superior, nasal, inferior and temporal quadrants were less in group 1 compared to controls, however this data was not statistically significant (p = 0.274, p = 0.149, p = 0326, p = 0783, respectively). In group 2, the RNFL thickness revealed a statistically significant decrease in all quadrants (p < 0.001) except temporal quadrant (p = 0.396). The mean duration of DM was significantly longer in group 2 (153.80 +/- 70.35) compared to group 1(60.76 +/- 50.41 months) (p < 0.001). However, there was no correlation between the RNFL thickness and the duration of DM. Conclusion: The RNFL thickness of patients with type 1 DM was found less compared to control subjects. This was more prominent in patients with established retinopathy (group 2). These findings suggested that the RNFL thickness measurement with the aid of OCT may be used as an adjunctive diagnostic tool for early diagnosis of DR.Öğe Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema(ELSEVIER SCIENCE INC, 2011) Ozturk, Banu Turgut; Kerimoglu, Hurkan; Adam, Mehmet; Gunduz, Kemal; Okudan, SuleymanPurpose: To evaluate the effect of glucose regulation on intravitreal ranibizumab injection for clinically significant diabetic macular edema (DME). Methods: This retrospective study enrolled 65 eyes of 65 patients with persistent DME treated with intravitreal ranibizumab injection. The main outcome measures were the change in best corrected visual acuity (BCVA), the central subfield macular thickness (CSMT) recorded with optical coherence tomography (OCT), and its correlation with the serum hemoglobin A(1c) values (HbA(1c)). Results: The study included 24 (36.9%) female and 41(63.1%) male patients with a mean age of 58.90 +/- 9.45 years. The mean HbA(1c) of the enrolled patients was 8.25 +/- 1.74% (range 5.7-12.7%). The median value of BCVA at baseline examination was 20/80 (52 letters), and the median CSMT was 468 pm (range 255-964 mu m). In the final control after 4-6 weeks following injection, the median value of BCVA increased to 20/50 (59.50 letters) and the median CSMT decreased to 310 pin (range 129-652 mu m). This change in BCVA and macular thickness was found to be significant (P<.001 for both). There was no correlation between BCVA and the change in macular thickness (coefficient=0.04, P=.78). The serum HbA(1c) values were found to be negatively correlated with the change in CSMT (coefficient=-0.50, P<.001). Conclusions: The results of intravitreal ranibizumab injection for DME demonstrated a beneficial effect on visual acuity and a decrease in CSMT which is inversely correlated with the serum HbA(1c), level. (C) 2011 Elsevier Inc. All rights reserved.Öğe Lumboperitoneal shunt in a patient with Behcet's disease with medically refractory intracranial hypertension(ELSEVIER SCI LTD, 2011) Dogan, Ebru Apaydin; Ozturk, Banu Turgut; Mutluer, Muzaffer; Yildiz, Gulce Unal; Genc, Emine; Yuruten, Betigul; Kocaogullar, YalcinA 21-year-old male presented with severe throbbing headache, nausea, vomiting and progressive visual loss. Clinical examination revealed bilateral papilledema and left abducens nerve palsy. MRI showed findings consistent with ducal sinus thrombosis. Combinging the clinical findings, MRI and a positive pathergy test, the patient was diagnosed with dural sinus thrombosis associated with Behcet's disease (BD). Despite acetazolamide, prednisone, azathioprine and repeated lumbar punctures, his signs and symptoms of intracranial hypertension gradually worsened. Therefore, lumboperitoneal shunting was planned after which rapid resolution of intracranial hypertension was observed. After reviewing similar reports, we suggest that lumboperitoneal shunt placement can be an effective treatment for patients with BD with medically refractory intracranial hypertension associated with dural sinus thrombosis. (C) 2010 Elsevier Ltd. All rights reserved.Öğe Ocular Changes Associated with Topiramate(TAYLOR & FRANCIS INC, 2011) Ozturk, Banu Turgut; Genc, Emine; Tokgoz, Mine; Kerimoglu, Hurkan; Genc, Bulent OguzPurpose: To determine the changes in refractive error, and the cornea, anterior chamber, and retina induced by topiramate. Methods: The study included 76 eyes of 38 patients that began to use topiramate due to migraine. Following ophthalmological examination, all of the patients underwent central corneal thickness (CCT), anterior chamber volume (ACV), anterior chamber depth (ACD), and anterior chamber angle (ACA) measurement using a Scheimpflug camera, as well as macular thickness, retinal and retinal nerve fiber layer thickness (RNFLT) measurements using optical coherence tomography (OCT). These procedures were repeated 15, 30, and 90 days after the initiation of topiramate therapy. Results: The median refractive error value showed a statistically significant increase from -0.25 diopters (D) to -0.62 D at the 90th day follow-up (P < 0.001). Mean CCT was 570.56 mu m before treatment and increased to 573.69 mu m at the 15th day follow-up, 575.31 mu m at the 30th day follow-up, and 574.56 mu m at the 90th day follow-up; however, these changes were not statistically significant. Mean ACV, ACD, and ACA did not exhibit statistically significant changes. Mean retinal thickness (RT) increased during the treatment from 263.46 mu m to 271.60 mu m, which was not statistically significant. The initial mean RNFLT was 100.56 +/- 15.36 mu m and significantly increased to 110.2 +/- 8.41 mu m and 111.03 +/- 14.59 mu m at the 30th and 90th day follow-ups, respectively (P = 0.01 and P = 0.004, respectively). Conclusions: During the 3-month follow-up of patients using topiramate 50 mg d(-1) significant myopic shift and an increase in RNFLT were observed. Further studies are warranted in order to assess the effects of topiramate when used long term and at higher doses.Öğe Postoperative fungal endophthalmitis caused by Trichosporon asahii treated with voriconazole(CONSEL BRASIL OFTALMOLOGIA, 2015) Gonul, Saban; Gedik, Sansal; Ozturk, Banu Turgut; Bakbak, Berker; Koktekir, Bengu Ekinci; Okudan, Suleyman; Dagi, Hatice TurkPostoperative fungal endophthalmitis is a rare but devastating complication of cataract surgery. Vitrectomy and intravitreal amphotericin B injection as well as administration of systemic antifungal agents have been suggested as optimal treatments for fungal endophthalmitis. However, this therapy may fail to eliminate fungal species resistant to current antifungal agents. The saprophytic fungus Trichosporon asahii is frequently observed as a cause of endogenous endophthalmitis in immunosuppressed patients. We report a case of postoperative endophthalmitis caused by T. asahii, resistant to amphotericin B. To the best of our knowledge, this is the first report of T. asahii endophthalmitis successfully treated with intravitreal and systemic voriconazole, pars plana vitrectomy, and removal of the intraocular lens and entire lens capsule.
